Our intention was to evaluate the relationships between the A-B neuropsychological assessment schedule (ABNAS) as a measure of patient-perceived cognitive effects of antiepileptic drugs (AEDs) and the results of neuropsychological tests. The measure was developed specifically to assess patient-perceived cognitive effects of AED treatment. Evidence of its reliability and validity has been previously documented. In this study 96 patients were included using stratified inclusion-criteria to guarantee variability of performance: 55 patients were included from a 'low risk condition' with respect to possible cognitive effect (i.e. monotherapy carbamazepine within a dose range of 600-1200 mg/day) and 41 patients were included from a 'high risk condition' (i.e. polytherapy of three or two AEDs including either phenytoin, phenobarbitone or a benzodiazepine; treatment with topiramate with a titration speed using 50 mg or higher increments per week and within the first 6 months of treatment). All patients were prospectively assessed using the ABNAS and five neuropsychological tests (all part of the FePsy test system) with proven sensitivity of cognitive effects of antiepileptics: three tasks using reaction-time to measure speed ('simple (visual) reaction-time measurement', 'the binary choice reaction test' and 'the computerized visual searching task'); one test measuring motor speed ('the finger tapping task'); and a memory test ('recognition of words'). The three reactiontime tasks and the finger tapping test were significantly correlated with the ABNAS-score with correlations ranging from 0.22 to 0.35. The highest correlation was with 'simple (visual) reaction-time measurement ' (0.35). Discriminant analysis showed that with the neuropsychological tests 61.5% of the patients were correctly identified as having high/low ABNAS-scores. The ABNAS underestimated impairment in 17.8% of the patients (= low ABNAS-score but impairment on the neuropsychological tests). The present study contributes to the already existing evidence of validity of the ABNAS as a screening instrument for clinical practice as the relationship between the ABNAS-score and results of neuropsychological tests can help to identify who is at risk and needs further referral for neuropsychological assessment. Moreover the correlation between ABNAS-score and those neuropsychological tests that are sensitive for drug-effects may provide a sensitive instrument in early drug-development phases while keeping the burden on financial and time resources to a minimum.
INTRODUCTION
The evaluation of adverse cognitive effects of antiepileptic drugs (AEDs) has gained prominence in recent years 20 ; as has the incorporation of the patient's perspective in treatment and research protocols. The importance of developing an instrument with sufficient reliability, validity, and sensitivity to reflect patientperceived drug-related cognitive impairments, while keeping the burden on financial and time resources to a minimum, was clear. The development of such an instrument-'The AB neuropsychological assessment schedule' (ABNAS; originally the A-B neurotoxicity scale)-has been undertaken by our group since 1993. The first step analysed clinical validity in a randomized, double-blind, parallel-group volunteer study 4 comparing three groups: 10 mg temazepam, 20 mg temazepam, and placebo. Significant differences were found in ABNAS-scores between placebo and the two temazepam groups indicating that adverse cognitive effects of drugs could be detected using this scale 4 . In addition, it became clear that the ABNAS-score represents a global report, i.e. revealing cognitive impairment irrespective of the type or severity of the impairments. It was therefore characterized as a screening instrument, identifying who is at risk of drug-induced cognitive impairment and thus providing a tool for referral for further neuropsychological evaluation.
Further validation of the instrument was undertaken in 1997 6 , with a specific focus on construct validity and reliability of the scale in 189 patients with chronic epilepsy and using polytherapy. In this 'worst case scenario', the ABNAS-scores for the epilepsy group were significantly higher than for the control group of volunteers on placebo. However, there were no significant differences between the scores of patients on monotherapy or polytherapy, on different dosages, or experiencing different levels of seizure frequency. Thus providing further support for the hypothesis that the ABNAS is a screening instrument, providing a global subjective report of impairment. Overall, results showed sufficient clinical sensitivity and excellent reliability and validity.
Recently the psychometric properties of the scale were analysed in detail, using specific techniques such as MAP-R analyses 11 . Results obtained from two populations: 200 patients with epilepsy and on medication and 200 controls without medication, showed that the ABNAS was not compromised by general effects such as age or gender. Moreover, the internal scales of the ABNAS showed excellent psychometric properties. The difference in scoring level between the controls and the patients with epilepsy was significant with almost three times higher scores for the patients with epilepsy.
So far one question remained unanswered. In clinical practice often patient complaints have to be interpreted, selecting those who need to be referred for further neuropsychological assessment. A correlation between the ABNAS-scores and neuropsychological tests may provide the clinician with a helpful tool for screening patients for further referral. Moreover, this is an important step in validating the ABNAS-scores, although correlations between patient complaints and results of neuropsychological tests are generally low in all kinds of clinical populations 15, 17, 18 . Correlating the ABNAS with neuropsychological tests is even more complex as patient perceived cognitive impairment may be subjectively interpreted as drugrelated (thus leading to a higher ABNAS-score), while the actual source may be different, e.g. seizurerelated. Nonetheless, we explored the relationships between the ABNAS-scores and results of a set of neuropsychological tests that has proven sensitivity for cognitive effects of AEDs 2, 5, 20 .
METHOD Trial design
We performed a clinical prospective comparative study. The patients were equally selected from the epilepsy outpatients clinic in the Walton Centre for Neurology and Neurosurgery, Liverpool, UK and from the Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands. To guarantee a sufficient variation in test scores:
-About half the patients were selected from a 'low risk condition', i.e. patients on monotherapy carbamazepine (CBZ). CBZ is a drug that is considered to have only mild effects on cognitive function when given within recommended therapeutic doses 2, 10, 19, 20 . All patients in this group had to be on steady-state treatment with monotherapy CBZ within the dose-range of 600-1200 mg/day for a minimum period of 4 months.
-About half the patients were selected from a 'high risk condition'. This could be: a polytherapy of three AEDs of which two had to be at clinical dose; or a combination therapy including either phenytoin, phenobarbitone or a benzodiazepine; or treatment with topiramate with a titration speed using 50 mg or higher increments per week and within the first 6 months of treatment 3, 7, 12, 16, 19, 20 .
All patients were prospectively assessed using psychometric tests and the ABNAS.
Inclusion and exclusion criteria

Inclusion
Patients had to be >18 years, of normal intelligence (established with the Wechsler Adult Intelligence Scale), a reconfirmed diagnosis of epilepsy and treatment with AEDs for a period of >4 months.
Exclusion
Patients were excluded on the basis of: a psychiatric history or current psychiatric treatment; treatment with other drugs than AEDs.
The patients were included in 1999/2000 and inclusion stopped after 40-50 patients were recruited from each risk condition.
Consent
An independent ethics committee approved the study. Subjects gave written informed consent before entering the study.
Instruments (1) Cognitive tests
We used tests that have demonstrated sensitivity for detecting cognitive side-effects of AEDs. This selection was based on consensus meetings, e.g. the workshop on measurement of drug-induced cognitive impairment during the 21st International Epilepsy Congress in Sydney 5 . All tests are part of the FePsy computerized neuropsychological test battery and are amply described elsewhere 1, 2, 8, 9 . The following areas/tests were included: Subjects were given ABNAS, assessing subjectively experienced side-effects. This scale is described elsewhere 4, 6, 11 . From this test we only used the overall score ranging from 0 (no side-effects reported on any of the 24 items) to 72 (score of 3-severe side-effects-on all 24 items). (Variable 6 is the total ABNAS-score: 0-72.) Variables 1-5 are the primary psychometric cognitive variables. Variable 6 is the primary variable for subjective cognitive experiences.
Statistical analysis
A sample size between 35 and 65 patients is sufficient to detect medium-size behavioural effects (i.e. changes of >0.5 standard deviation, following Cohen's conventions 13, 14 ; see also reference 20) with a significance level of 5% and a Beta of type-2 error risk (ß) of 20% (see the psychometric qualities of the scale in Brooks et al., 2001 ). Medium-size effects are generally seen as behavioural effects of antiepileptics 2, 20 . We aimed at including >40 patients per 'risk condition' (see section on inclusion). Therefore inclusion stopped after 40-50 patients were included from each risk condition, resulting in a total sample size between 80 and 100 patients. The results were analysed using correlational analysis to compare the psychometric results with the ABNAS-score, discriminant analysis and cluster analysis to inspect the possibility of using the ABNAS to screen patients. Statistical analysis was performed using SPSS/PC V9.1. 
RESULTS
Within the study period, 96 subjects met the inclusion criteria, 55 from the 'low risk condition' (monotherapy CBZ) and 41 from the 'high risk condition'. None of the subjects withdrew consent. Table 1 shows the demographic and clinical characteristics for the study population.
The majority of the patients had a localized-related (partial) epilepsy with complex partial seizures, with or without secondary generalization. The average age was 37.5 years and there was no significant difference with respect to gender (55 male, 41 female). The intelligence rating was average (WAIS full scale IQ: 107; SD 13.4) and educational background ranged from lower secondary education (31.7%) to higher forms of education (7.3%). Intelligence was similar for the two conditions (F: 1.008; P = 0.33). Medication was monotherapy CBZ for the 'low risk condition' (average daily dose of 945 mg) and a high variability of medications and dosing for the 'high risk condition' (see inclusion criteria). Differences in distribution of seizure types between the two selection-conditions (high risk/low risk condition) were not statistically significant: simple partial seizures: χ 2 = 2.133, P = 0.144; complex partial seizures: χ 2 = 2.667, P = 0.102; secondary generalized seizures: χ 2 = 2.000, P = 0.157. Patients in the high risk condition had a higher seizure frequency for simple partial seizures (P = 0.01) and for secondary generalized seizures (P = 0.03). Table 2 shows an average score on the ABNAS scale of 19.46 for the total group (SD. 15.8), which concurs with our results in a similar group with chronic epilepsy (average ABNAS-score of 20.6 6 ) and the epilepsy group in our recent study 11 . There is a difference between the low risk and high risk condition (18.64 vs. 20.56), but this difference is not statistically significantly different (P = 0.55). The scores on the neuropsychological tests are in accordance with scores in a population with epilepsy 1, 2, 8, 9 . Table 3 shows the results of the correlational analysis between the results of the neuropsychological tests and the ABNAS-score. Statistically significant correlations are found for all tests except for the 'the word recognition task'. The correlations for the remaining four tasks are in the range of 0.22-0.35. Highest correlation is with 'simple (visual) reactiontime measurement' (0.35). The correlations are all in the expected direction (for the three reaction-time tasks a higher score on the ABNAS correlates with slower reaction: for 'the finger tapping task' a higher score on the ABNAS correlates with lower tapping level and is thus negative).
Discriminant analysis was used to explore the number of patients that can be correctly classified with respect to their ABNAS-score, using the results on the neuropsychological tests combined. This technique thus uses the results of the neuropsychological tests combined and inspects whether this correlates with the ABNAS-score. To be able to perform discriminant analysis (that uses a limited number of groups to classify), the ABNAS-scores were dichotomized in 'low scores' (scores <15 n = 45) and 'high scores' (scores >15 n = 51). The cut-off point of 15 was derived from the scores obtained in the control groups in the studies 2, 6, 11 . Using the scores of the neuropsychological tests combined, 61.5% of the patients were correctly identified as having high vs. low ABNAS-scores. The classification table (Table 4) shows that the neuropsychological tests sufficiently identify low ABNAS-scores (82.2% of the low ABNAS-scores, correctly identified) and a reasonable percentage of the high scores (43.1%). A low score on the ABNAS is thus associated with normal scores on the neuropsychological impairments for the majority of the patients (82.2%) and the ABNAS fails to identify impairment in 17.8% of the patients (= low ABNAS-score but subnormal scores on the neuropsychological tests). A high score on the ABNAS is not always associated with impairment on these neuropsychological tests. This latter finding concurs with the failure to show statistically significant differences for the ABNASscore between patients included from a 'low risk condition' (CBZ monotherapy) and the patients included from a 'high risk condition' (polytherapy): see Table 2: 18.64 vs. 20.56 (P = 0.55). This does not necessarily invalidate the ABNAS, as patients may in fact not have cognitive side-effects, despite the 'high risk' condition that they are exposed to. Vice versa, a monotherapy of CBZ will normally not lead to negative cognitive effects, but some patients will be an exception. Finally for many patients it will be difficult to identify the exact origin of the cognitive impairment. They may subjectively experience cognitive difficulties and associate these with the medication (and thus report this on the ABNAS), although the actual cause may be the epilepsy or the epileptic seizures. A patient included from the 'low risk condition' of monotherapy CBZ may, for example, have cognitive effects caused by insufficient seizure control. Irrespective of the cause, the result may be a high score on the ABNAS. As the aim of this study was to identify the relationships between neuropsychological test performance and the ABNAS-score, we rearranged 'high risk condition' vs. 'low risk condition' using cluster analysis, based on rank scores for the neuropsychological tests combined. All subjects thus received a rank score based on their scores on the neuropsychological tests combined. In total, 21 of the 96 patients were replaced, based on their neuropsychological scores and the new clusters were identified as 'not neuropsychologically impaired' (n = 53) and 'neuropsychologically impaired' (n = 43). The patients in the 'neuropsychologically impaired cluster' are thus patients that have the lowest scores on the combined neuropsychological tests, irrespective of whether this is caused by the medication or by other factors. After this reclassification the ABNAS-scores are statistically different (t-value −2.779 P = 0.007) as shown in Table 5 with the highest ABNAS-score for the 'neuropsychologically impaired group' (15.55 vs. 24.28). 
DISCUSSION
This study contributes to the development of the ABNAS, an instrument aimed at assessing patientperceived drug-related cognitive impairment. In this study the outcome of a subjective report (total score of the ABNAS) was compared with the results on those neuropsychological tests that are generally used to assess cognitive side-effects of AEDs. This is a relevant phase in the validation process of an instrument, given its use as a screening instrument. The results can be used in the decision-making process to refer a patient for further neuropsychological evaluation.
Our results show modest but statistically significant correlations between the ABNAS and the neuropsychological tests, which is remarkable given the absence of such correlations between subjective measurements and results of tests in a number of other clinical conditions 15, 17, 18 . Our study analysed correlations in 96 patients with reconfirmed epilepsy, included from two different conditions: a 'low risk condition' (monotherapy CBZ) and a 'high risk condition' (basically polytherapy). This inclusion procedure aimed at achieving sufficient variations of scores in the study sample. Statistically significant correlations between the overall ABNAS-score and the neuropsychological tests were found for all 'speed tests': 'simple (visual) reaction-time measurement', 'binary choice reaction-time measurement' and the 'visual searching task' (CVST); all three using reaction-time as the primary outcome and 'the finger tapping task' (motor speed and fluency), with correlations ranging from 0.22 to 0.35. The highest correlation was with 'simple (visual) reaction-time measurement' (0.35). This is in line with findings of neuropsychological studies that consistently identify 'speed factors' as the most sensitive area in relation to drug treatment 16, 19, 20 , specifically psychomotor speed that is primarily measured with 'simple (visual) reaction-time measurement'. The correlations were all in the expected direction (for the three reaction-time tasks a higher score on the ABNAS correlates with slower reaction-time, for the finger tapping task a higher score on the ABNAS correlates with lower tapping level). The memory test was not correlated with the ABNAS-score.
Although statistically significant, most correlations are relatively modest (0.35 at maximum), which indicates that other factors have a strong impact on the ABNAS-scores: the epilepsy and its underlying aetiology or the seizures. This concurs with the absence of a significant difference in ABNAS-scores between the two groups included in this study: 'high risk condition' and 'low risk condition'. A score of a patient in the 'low risk condition' may nevertheless be high because other factors are involved with potential effect on cognitive function, such as the effect of insufficiently controlled seizures. The ABNAS provides a subjective score: the patient reports cognitive impairment and although he/she infers that this is a drug-induced effect (which is an important sign in clinical practice), it may be impossible for the patient to separate druginduced effects from other sources inducing cognitive impairment. This is even more complicated as these factors often occur in the same period: when seizure frequency increases, this is often followed by drug changes and when cognitive impairments develop in this period, both the increase of seizure frequency and the drug changes could be responsible for the cognitive impairments. Whatever source, an important aspect of the validity of the ABNAS is that a high score indicates neuropsychological difficulties. When the patients were classified on the basis of ranks on the neuropsychological tests, the ABNAS-score was statistically significantly different, with a 60% higher score for the patients with lowest neuropsychological ranks (15.55 vs. 24.28 ).
This was also demonstrated with a classification analysis technique: discriminant analysis. Using the neuropsychological tests combined 61.5% of the patients were correctly identified as having high or low ABNAS-scores. Important for clinical practice is that a low ABNAS-score correctly identifies the absence of neuropsychological impairment as measured by the neuropsychological tests (82.2% of the low ABNASscores are associated with normal neuropsychological scores). A low score on the ABNAS will thus fail to identify actual neuropsychological impairment only in 17.8% of the patients.
When we now combine the results of the four studies that we performed with the ABNAS 4, 6, 11 , the present study, we may conclude that the ABNAS has validity as a screening instrument for both clinical practice and for drug trials with sufficient reliability, sensitivity for change and internal consistency. Moreover we now have established that the ABNAS is sufficiently related with the outcomes of both neuropsychological assessment with the FePsy computerized test battery (present study) and the results of mood rating scales 11 , to be used for screening patients who are at risk of drug-induced behavioural impairment. Moreover, the correlation between ABNAS-score and those neuropsychological tests that are sensitive for drug-effects may provide a sensitive instrument in early drug-development phases while keeping the burden on financial and time resources to a minimum.
